Nancy A Simonian
CIK 1359574 · President & CEO · last filed 2026-03-02
Nancy A Simonian is a President & CEO who has filed 52 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for GENB, was dated Mar 2, 2026. Across all open-market trades the lifetime net is −$2.1M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
5
52
-$2.15M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GENB | Director | — | $12.96 | — | $0 | 1 | 2026-03-02 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 12,000 | $0.00 | $5 | -$45.8K | 22 | 2024-12-04 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | $0 | 14 | 2023-12-15 |
| Evelo Biosciences, Inc. (EVLO) Delisted | Director | — | $0.00 | — | $0 | 3 | 2020-06-18 |
| MILLENNIUM PHARMACEUTICALS INC (MLNM) Delisted | Chief Medical Officer | 4,975 | — | — | -$2.10M | 6 | 2008-05-15 |
Recent Filings
52 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-02 | GENB | Grant (A) | — | $0 | EDGAR |
| 2024-12-04 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Sell (S) | −37,070 | -$10.0K | EDGAR |
| 2024-12-02 | — | Notice (144) | −37,070 | -$10.0K | EDGAR |
| 2024-11-27 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Sell (S) | −134,713 | -$35.7K | EDGAR |
| 2024-11-25 | — | Notice (144) | −134,713 | -$26.9K | EDGAR |
| 2024-11-04 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Exer (M) | +40,125 | $0 | EDGAR |
| 2024-06-07 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Grant (A) | +4,000 | $0 | EDGAR |
| 2024-04-02 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Mixed | +31,514 | -$71.9K | EDGAR |
| 2023-12-15 | Seagen Inc. (SGEN) Delisted | Disp (D) | −62,753 | -$14.37M | EDGAR |
| 2023-12-05 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Disp (D) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.